Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline

Executive Summary

• Defence Therapeutics announced an expanded collaboration with Canadian Nuclear Laboratories (CNL) to broaden its radiopharmaceutical portfolio using the Accum® platform.
• The partnership will now include multiple new radioisotope programs aimed at generating data for candidate selection and first‑in‑human clinical studies.
• Both companies highlighted the strategic importance of the alliance, positioning radiopharmaceuticals as a top development priority alongside Defence’s ADC program.

Key Details

• Existing collaboration on an Accum®‑enhanced radio‑immunoconjugate program is reaching a “key inflection point” with critical laboratory results supporting candidate selection.
• Expansion will initiate multiple additional radioisotope programs leveraging Defence’s proprietary Accum® technology and CNL’s nuclear science expertise.
• The new work is intended to generate data that will enable preparation for first‑in‑human clinical studies on the lead program and future candidates.
• CEO Sébastien Plouffe stated the collaboration is a “cornerstone of our radiopharmaceutical strategy” and places radiopharmaceuticals among the company’s top development priorities.
• Dr. Monica Regalbuto, Vice‑President Science & Technology at CNL, affirmed CNL’s commitment to providing technical results and nuclear science expertise for advancing Defence’s pipeline.
• No financial terms, financing arrangements, or M&A considerations were disclosed in this release.

Notable Quotes

“This collaboration with CNL has become a cornerstone of our radiopharmaceutical strategy,” – Sébastien Plouffe, CEO, Defence Therapeutics.

“We have worked in close collaboration with Defence on their flagship program… we look forward to contributing our nuclear science expertise to help advance these programs toward the clinic.” – Dr. Monica Regalbuto, Vice‑President, Science & Technology, CNL.